Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Melanoma 1DNA Repair-Deficiency Disorders 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2331Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1784Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 936Prednisone 926Cetuximab 921Lenalidomide 916Trastuzumab 902

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × omega-N-Methylarginine × Clear all
NCT05660083 2026-06-04

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

The Methodist Hospital Research Institute

Phase 2 Recruiting
36 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03236935 2026-04-09

Phase Ib of L-NMMA and Pembrolizumab

The Methodist Hospital Research Institute

Phase 1 Completed
12 enrolled 15 charts
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, DNA Repair-Deficiency Disorders

NCT02834403 2023-12-15

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

The Methodist Hospital Research Institute

Phase 1/2 Completed
37 enrolled 20 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡